Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Drug Discovery
Overview
Conditions
Intellectual Property
Research
R&D Pipeline
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma
Name:
Email:

Yes, in addition to e-alerts, please sign me up to receive Nutra Pharma Blog postings via email.

Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Conditions

Nutra Pharma, through its subsidiary ReceptoPharm, is taking on some of the world's most difficult diseases including Multiple Sclerosis, HIV/AIDS, Adrenomyeloneuropathy, and Herpes.

RPI-MN: Modified Cobra Venom for Viral Diseases

Herpes
Herpes is a group of related diseases marked by the development of blisterlike sores on the skin or mucous membranes of the body.
 
 
Human Immunodeficiency Virus (HIV / AIDS)
The Human Immunodeficiency Virus (HIV) is the virus that causes AIDS, a debilitating and deadly disease of the human immune system. The World Health Organization (WHO) estimates that 20 million people have died from AIDS since 1981. It is estimated that at the end of 2001, there were more than 40 million people worldwide infected with HIV and living with the virus or AIDS.
 
 
Rabies
Rabies is an infectious and often fatal viral disease transmitted by the bite of an infected animal. The disease attacks the central nervous system.
 

RPI-78M: Modified Alpha Cobratoxin for Autoimmune Diseases

Adrenomyeloneuropathy (AMN)
Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder that effects approximately 20,000 people globally. Its symptoms are very similar to those of progressive Multiple Sclerosis (MS).
Additional Information: AMNHelp
 
 
Multiple Sclerosis (MS)
Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system causing muscular weakness, loss of coordination, and speech and visual disturbances.
 
Quick Nav
 
Recent News
August 14, 2008
Nutra Pharma Announces Initial Positive Safety Data from Clinical Study in Adrenomyeloneuropathy (AMN)


August 6, 2008
Nutra Pharma Announces Collaborative Agreement with Centers for Disease Control and Prevention (CDC)


August 1, 2008
August 2008 Shareholder Letter from Chairman and CEO Rik J. Deitsch


 
 
Announcements
Click Here for an Update on the Phase IIb Clinical Trial Data.
 
 
NPC
Privacy Policy